BIORESTORATIVE THERAPIES INC (BRTX) Fundamental Analysis & Valuation

NASDAQ:BRTX • US0906556065

Current stock price

0.3269 USD
+0.05 (+16.79%)
At close:
0.3199 USD
-0.01 (-2.14%)
After Hours:

This BRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BRTX Profitability Analysis

1.1 Basic Checks

  • In the past year BRTX has reported negative net income.
  • In the past year BRTX has reported a negative cash flow from operations.
  • BRTX had negative earnings in each of the past 5 years.
  • In the past 5 years BRTX always reported negative operating cash flow.
BRTX Yearly Net Income VS EBIT VS OCF VS FCFBRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • BRTX has a worse Return On Assets (-224.55%) than 89.98% of its industry peers.
  • BRTX has a Return On Equity of -574.11%. This is in the lower half of the industry: BRTX underperforms 77.07% of its industry peers.
Industry RankSector Rank
ROA -224.55%
ROE -574.11%
ROIC N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRTX Yearly ROA, ROE, ROICBRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • BRTX has a better Gross Margin (93.35%) than 94.03% of its industry peers.
  • BRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRTX Yearly Profit, Operating, Gross MarginsBRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BRTX Health Analysis

2.1 Basic Checks

  • BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BRTX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BRTX has more shares outstanding
  • BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRTX Yearly Shares OutstandingBRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BRTX Yearly Total Debt VS Total AssetsBRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -48.46, we must say that BRTX is in the distress zone and has some risk of bankruptcy.
  • BRTX's Altman-Z score of -48.46 is on the low side compared to the rest of the industry. BRTX is outperformed by 91.14% of its industry peers.
  • There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.46
ROIC/WACCN/A
WACC9.32%
BRTX Yearly LT Debt VS Equity VS FCFBRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 1.37 indicates that BRTX should not have too much problems paying its short term obligations.
  • BRTX has a Current ratio of 1.37. This is amonst the worse of the industry: BRTX underperforms 83.43% of its industry peers.
  • A Quick Ratio of 1.37 indicates that BRTX should not have too much problems paying its short term obligations.
  • The Quick ratio of BRTX (1.37) is worse than 82.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.37
BRTX Yearly Current Assets VS Current LiabilitesBRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BRTX Growth Analysis

3.1 Past

  • BRTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.17%.
  • Looking at the last year, BRTX shows a small growth in Revenue. The Revenue has grown by 1.70% in the last year.
  • BRTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.27% yearly.
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.27%
Revenue 1Y (TTM)1.7%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-94.87%

3.2 Future

  • Based on estimates for the next years, BRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 49.08% on average per year.
  • Based on estimates for the next years, BRTX will show a very strong growth in Revenue. The Revenue will grow by 169.97% on average per year.
EPS Next Y-42.84%
EPS Next 2Y15.88%
EPS Next 3Y13.13%
EPS Next 5Y49.08%
Revenue Next Year-41.18%
Revenue Next 2Y51.03%
Revenue Next 3Y54.34%
Revenue Next 5Y169.98%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BRTX Yearly Revenue VS EstimatesBRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
BRTX Yearly EPS VS EstimatesBRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. BRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • BRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRTX Price Earnings VS Forward Price EarningsBRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRTX Per share dataBRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • BRTX's earnings are expected to grow with 13.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.88%
EPS Next 3Y13.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BRTX Dividend Analysis

5.1 Amount

  • BRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRTX Fundamentals: All Metrics, Ratios and Statistics

BIORESTORATIVE THERAPIES INC

NASDAQ:BRTX (3/23/2026, 8:00:01 PM)

After market: 0.3199 -0.01 (-2.14%)

0.3269

+0.05 (+16.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-26
Inst Owners5.38%
Inst Owner Change-13.21%
Ins Owners6.03%
Ins Owner Change0%
Market Cap7.06M
Revenue(TTM)383.40K
Net Income(TTM)-12.67M
Analysts82.5
Price Target9.69 (2864.21%)
Short Float %4.25%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)10.13%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)-7.91%
Min EPS beat(4)-93.06%
Max EPS beat(4)28.7%
EPS beat(8)7
Avg EPS beat(8)13.38%
EPS beat(12)10
Avg EPS beat(12)12.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.04%
Min Revenue beat(2)-97.44%
Max Revenue beat(2)-12.63%
Revenue beat(4)0
Avg Revenue beat(4)-73.67%
Min Revenue beat(4)-97.44%
Max Revenue beat(4)-12.63%
Revenue beat(8)3
Avg Revenue beat(8)38.19%
Revenue beat(12)6
Avg Revenue beat(12)44.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.92%
PT rev (3m)-26.92%
EPS NQ rev (1m)3.9%
EPS NQ rev (3m)1.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-41.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.43
P/FCF N/A
P/OCF N/A
P/B 3.2
P/tB 4.28
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.02
BVpS0.1
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -224.55%
ROE -574.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.35%
FCFM N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.51%
Cap/Sales 12.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.37
Altman-Z -48.46
F-Score3
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)175.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)170.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.27%
EPS Next Y-42.84%
EPS Next 2Y15.88%
EPS Next 3Y13.13%
EPS Next 5Y49.08%
Revenue 1Y (TTM)1.7%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-94.87%
Revenue Next Year-41.18%
Revenue Next 2Y51.03%
Revenue Next 3Y54.34%
Revenue Next 5Y169.98%
EBIT growth 1Y-20.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-64.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.1%
OCF growth 3YN/A
OCF growth 5YN/A

BIORESTORATIVE THERAPIES INC / BRTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIORESTORATIVE THERAPIES INC?

ChartMill assigns a fundamental rating of 3 / 10 to BRTX.


What is the valuation status of BIORESTORATIVE THERAPIES INC (BRTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIORESTORATIVE THERAPIES INC (BRTX). This can be considered as Overvalued.


What is the profitability of BRTX stock?

BIORESTORATIVE THERAPIES INC (BRTX) has a profitability rating of 1 / 10.